Sickle cell drug faces FDA timing and safety-structure questions

Agios’ supplemental NDA for mitapivat in sickle cell disease has hit a regulatory timing snag, with the FDA extending the PDUFA action date by three months to February 1, 2027. The agency cited a major amendment tied to whether a Risk Evaluation and Mitigation Strategy (REMS) is needed for the SCD indication.